Hannah Almuttaqi

Hannah Almuttaqi

Auto-generated profile, based on publicly available information

Hannah Almuttaqi

Kennedy Institute of Rheumatology, University of Oxford, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Molecular Systems Biology
Verified
Journal Article
Open access
PDF file
JSJulia E Sero
Julia E Sero
HSHeba Sailem
Heba Sailem
RARico Chandra Ardy
Rico Chandra Ardy
HAHannah Almuttaqi
Hannah Almuttaqi
TZTongli Zhang
Tongli Zhang
CBChris Bakal
Chris Bakal
Although a great deal is known about the signaling events that promote nuclear translocation of NF‐κB, how cellular biophysics and the microenvironment might regulate the dynamics of this pathway is poorly understood. In this study, we used high‐content image analysis and Bayesian network modeling to ask whether cell shape and context features influence NF‐κB activation using the inherent variability present in unperturbed populations of breast tumor and non‐tumor cell lines. Cell–cell contact, cell and nuclear area, and protrusiveness all contributed to variability in NF‐κB localization in the absence and presence of TNFα. Higher levels of nuclear NF‐κB were associated with mesenchymal‐like versus epithelial‐like morphologies, and RhoA‐ROCK‐myosin II signaling was critical for mediating shape‐based differences in NF‐κB localization and oscillations. Thus, mechanical factors such as cell shape and the microenvironment can influence NF‐κB signaling and may in part explain how different phenotypic outcomes can arise from the same chemical cues.

10 September 2018 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
HAHannah Almuttaqi
Hannah Almuttaqi
IUIrina A. Udalova
Irina A. Udalova
Interferon regulatory factor 5 (IRF5) belongs to a family of transcription factors, originally implicated in antiviral responses and interferon production. However, studies conducted in different laboratories over the last decade have placed IRF5 as a central regulator of the inflammatory response. It has become clear that IRF5 contributes to the pathogenesis of many inflammatory and autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease and systemic lupus erythematosus. Given the role of IRF5 in physiology and disease, IRF5 represents a potential therapeutic target. However, despite a significant interest from the pharmaceutical industry, inhibitors that interfere with the IRF5 pathway remain elusive. Here, we review the advances made by various studies in targeting multiple steps of signalling leading to IRF5 activation with their therapeutic potential, and the possible complications of such strategies are discussed.